Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection

References

• Schaper KJ, Schubert S, Dalhoff A. Kinetics and quantification of antibacterial effects of β-lactams, macrolides, and quinolones against Gram-positive and Gram-negative RTI pathogens. Infection33(Suppl. 2), S3–S14 (2005).
   PubMedGoogle Scholar
• Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. In: Antibiotics in Laboratory Medicine. Lorian V (Ed.), Williams and Wilkins, MD, USA, 367–402 (1991).
   Google Scholar
• Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo.J. Antimicrob. Chemother.11, 233–238 (1983).
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamic: a critical review. Int. J. Antimicrob. Agents19, 261–268 (2002).
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/ pharmacodynamic indices: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis.26, 1–12 (1998).
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin–clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother.42, 2375–2379 (1998).
   PubMed Web of Science ®Google Scholar
• Scaglione F, Mouton JW, Mattina R, Fraschini F. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob. Agents Chemother.47, 2749–2755 (2003).
   PubMed Web of Science ®Google Scholar
• Craig WA, Dalhoff A. Pharmacodynamics of fluoroquinolones in experimental animals. In: Handbook of Experimental Pharmacology: Quinolone Antibacterials. Vol. 127. Kulman J, Dalhoff A, Zeiler HJ (Eds). Springer-Verlag Berlin, Heidelberg, Germany, 207–232 (1998).
   Google Scholar
• Craig WA. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. In: Expanding Indications for the New Macrolides, Azalindes and Streptogramin. Zinner SH, Young LS, Acar JF, Neu HC (Eds), Marcel Dekker, NY, USA, 27–38 (1997).
   Google Scholar
• Craig WA. Does the dose matter? Clin. Infect. Dis.33(Suppl. 3), S233–S237 (2001).
   PubMed Web of Science ®Google Scholar
• Drusano GL. Prevention of resistance: a goal for dose selection of antimicrobial agents. Clin. Infect. Dis.36(Suppl. 1), S42–S50 (2003).
   PubMed Web of Science ®Google Scholar
• Turnidge JD. The pharmacodynamics of β-lactams. Clin. Infect. Dis.27, 10–22 (1998).
   PubMed Web of Science ®Google Scholar
• Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J.77(Suppl. 6), S7–S11 (1998).
   PubMedGoogle Scholar
• Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect. Dis. Clin. North Am.12(4), 849–860 (1998).
   PubMed Web of Science ®Google Scholar
• Mouton JW, Punt N. Use of the T>/MIC to choose between different dosing regimens of β-lactam antibiotics. J. Antimicrob. Chemother.47(4), 500–501 (2001).
   PubMed Web of Science ®Google Scholar
• Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet.39(3), 185–201 (2000).
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J.15, 255–259 (1996).
   PubMed Web of Science ®Google Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch. Intern. Med.160, 1399–1408 (2000).
   PubMed Web of Science ®Google Scholar
• Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis.22, 89–96 (1995).
   PubMed Web of Science ®Google Scholar
• Craig WA, Ebert S, Watanabe Y. Differences in time above MIC required for efficacy of β-lactams in animal infection models. Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). American Society for Microbiology, Washington, DC, USA, Abstract 86 (1993).
   Google Scholar
• Navarro AS. New formulation of amoxicillin/clavulanic acid. A pharmacokinetic and pharmacodynamic review Clin. Pharmacokinet.44(11), 1097–1115 (2005).
   PubMed Web of Science ®Google Scholar
• Craig WA. Proof of concept: performance testing in models. Clin. Microb. Infect.10(Suppl. 2), S12–S17 (2004).
   Google Scholar
• Dagan AR, Klugman KP, Craig WA Baquero AF. Evidence to support the rationale that bacterial eradication in respiratory tract infections is an important aim of antimicrobial therapy. J. Antimicrob. Chemother.47, 129–140 (2001).
   PubMed Web of Science ®Google Scholar
• Vondracek TG. β-lactam antibiotics: is continuous infusion the preferred method of administration? Ann. Pharmacother.29, 415–424 (1995).
   PubMed Web of Science ®Google Scholar
• Nightingale CH, Quintilliani R, Nicolau DP. Intelligent dosing of antimicrobials. In: Current Clinical Topics in Infectious Disease, vol. 14. Remington SC, Swartz MN (Eds), Blackwell Scientific Publishers (1994).
   Google Scholar
• Bodey GP, Ketchel SJ, Rodriguez VA. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am. J. Med.67, 608–616 (1979).
   PubMed Web of Science ®Google Scholar
• MacGowan AP, Bowker KE. Continuous infusion of β-lactam antibiotics. Clin. Pharmacokinet.35, 391–402 (1998).
   PubMed Web of Science ®Google Scholar
• Angus BJ, Smith D, Suputtamongkol Y et al. Pharmacokinetic–pharmacodynamic evaluation of ceftazidime continuous infusion vs. intermittent bolus injection in septicaemic melioidosis. Br. J. Clin. Pharmacol.49, 445–452 (2000).
   PubMed Web of Science ®Google Scholar
• Egerer G, Goldschmidt H, Salwender H et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high dose chemotherapy and peripheral blood stem transplantation. Int. J. Antimicrob. Agents15, 119–123 (2000).
   PubMed Web of Science ®Google Scholar
• Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int. J. Antimicrob. Agents17, 497–504 (2001).
   PubMed Web of Science ®Google Scholar
• Frei CR, Burgess DS. Continuous infusion β-lactam for intensive care unit pulmonary infections. Clin. Microbiol. Infect.11(5), 418–421 (2005).
   PubMed Web of Science ®Google Scholar
• Kuti JL, Nightingale CH, Quintiliani R et al. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn. Microbiol. Infect. Dis.44, 51–57 (2002).
   PubMed Web of Science ®Google Scholar
• Vinks AA, den Hollander JG, Overbeek SE et al. Population pharmacokinetic analysis of nonlinear behaviour of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob. Agents Chemother.47, 541–547 (2003).
   PubMed Web of Science ®Google Scholar
• Buck C, Bertram N, Ackermann T, Paar WD. Phatmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion Int. J. Antimicrob. Agents25, 62–67 (2005).
   PubMed Web of Science ®Google Scholar
• Munckoff WJ, Carney J, Neilson G, Whitby M. Continuous infusion of ticarcillin–clavulanate for home treatment of serious infection: clinical efficacy, safety, pharmacokinetics and pharmacodynamics Int. J. Antimicrob. Agents25, 514–522 (2005).
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect. Dis.5, 581–589 (2005).
   PubMed Web of Science ®Google Scholar
• Baririan N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J. Antimicrob. Chemother.51, 651–658 (2003).
   PubMed Web of Science ®Google Scholar
• Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem. Pharmacol.71, 1085–1095 (2006).
   PubMed Web of Science ®Google Scholar
• Bustamente CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa.Antimicrob. Agents Chemother.26, 678–682 (1984).
   PubMed Web of Science ®Google Scholar
• Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. PharmacoEconomics20, 513–528 (2002).
   PubMed Web of Science ®Google Scholar
• Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Role of pharmacodynamics in designing dosage regimens for β-lactams. Conn. Med.67, 265–268 (2003).
   PubMedGoogle Scholar
• Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Therapeutics26(8), 1187–1198 (2004).
   PubMed Web of Science ®Google Scholar
• Viaene E, Chanteux H, Servais H et al. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother.46, 2327–2332 (2002).
   PubMed Web of Science ®Google Scholar
• Thalhammer F, Traunmuller F, El Menyawi I et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother.43, 523–527 (1999).
   PubMed Web of Science ®Google Scholar
• Grant EM, Zhong MK, Ambrose PG et al. Stability of meropenem in a portable infusion device in a cold pouch. Am. J. Health Syst. Pharm.57, 992–995 (2000).
   PubMed Web of Science ®Google Scholar
• Kuti JL, Nightingale CH, Knauft RF Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis Clin. Therapeutics26(4), 493–501 (2004).
   PubMed Web of Science ®Google Scholar
• Maglio D, Nightingale CH, Nicolau DP. Extended interval aminoglycoside dosing: from concept to clinic Int. J. Antimicrob. Agents19, 341–348 (2002).
   PubMed Web of Science ®Google Scholar
• Noone P, Pattison JR. The effective use of gentamicin in life threatening sepsis. Postgrad. Med.50(Suppl. 4), S9–S16 (1974).
   Google Scholar
• Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med.77, 657–662 (1984).
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J. Infect. Dis.149, 443–448 (1984).
   PubMed Web of Science ®Google Scholar
• Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis.155, 93–99 (1987).
   PubMed Web of Science ®Google Scholar
• Craig WA, Leggett J, Totsuka K, Vogelman B. Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections. J. Drug Dev.1(Suppl. 3), S7–S15 (1988).
   Google Scholar
• Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect. Control. Hosp. Epidemiol.11, 319–326 (1990).
   PubMed Web of Science ®Google Scholar
• Giuliano RA, Verpooten GA, Verbist L, Wedeen R, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J. Pharmacol. Exp. Ther.236, 470–475 (1986).
   PubMed Web of Science ®Google Scholar
• Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J. Infect. Dis.140, 576–580 (1979).
   PubMed Web of Science ®Google Scholar
• De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J. Antimicrob. Chemother.27(Suppl. C), S41–S47 (1991).
   PubMed Web of Science ®Google Scholar
• LeBrun M, Grenier L, Gourde P et al. Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration. Antimicrob. Agents Chemother.43, 1020–1026 (1999).
   PubMed Web of Science ®Google Scholar
• Prins JM, Weverling GJ, van Ketel RJ et al. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin. Pharmacol. Ther.62, 106–111 (1997).
   PubMed Web of Science ®Google Scholar
• Brummett RE. Ototoxicity of aminoglycoside antibiotics in animal models. INSERM102, 359–376 (1982).
   Google Scholar
• Tran Ba Huy P, Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta. Otolaryngol.105, 511–515 (1988).
   PubMed Web of Science ®Google Scholar
• Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J. Am. Med. Assoc.279(2), 125–129 (1998).
   PubMed Web of Science ®Google Scholar
• Drusano GL. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. J. Chemother.12(Suppl. 4), S21–S26 (2000).
   Google Scholar
• Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother.37, 483–490 (1993).
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch. Intern. Med.149, 2269–2273 (1989).
   PubMedGoogle Scholar
• Lee BL, Padula AM, Kimbrough RC et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med.325, 520–521 (1991).
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother.37, 1073–1081 (1993).
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Owens RC. Clinical pharmacodynamics of quinolones. Infect. Dis. Clin. North Am.17, 529–543 (2003).
   PubMed Web of Science ®Google Scholar
• Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother.47, 292–296 (2003).
   PubMed Web of Science ®Google Scholar
• Owens RC, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic–pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae.Diagn. Microbiol. Infect. Dis.51, 45–49 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect.7, 589–596 (2001).
   PubMed Web of Science ®Google Scholar
• Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis.33(Suppl. 3), S147–S156 (2001).
   PubMed Web of Science ®Google Scholar
• Firsov AA, Vostrov SN, Lubenko IY et al.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Antimicrob. Agents Chemother.47, 1604–1613 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother.46, 522–524 (2002).
   PubMed Web of Science ®Google Scholar
• Zinner SH, Lubenko IY, Gilbert D et al. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing J. Antimicrob. Chemother.52, 616–622 (2003).
   PubMed Web of Science ®Google Scholar
• Goldman RC, Scaglione F. The macrolide–bacterium interaction and its biological basis. Curr. Drug Targets Infect. Disord.4(3), 241–260 (2004).
   PubMedGoogle Scholar
• Craig WA. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. Respir. Med.95(Suppl. A), S12–S19 (2001).
   Google Scholar
• Craig WA, Keim S, Andes DR. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, Abstract A-1264 (2002).
   Google Scholar
• Babl FE, Pelton SI, Li Z. Experimental acute otitis media due to non typeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. Antimicrob. Agents Chemother.46, 2194–2199 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen R, Reinert P, de la Rocque F et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr. Infect. Dis. J.21, 297–303 (2002).
   PubMed Web of Science ®Google Scholar
• Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin. Infect. Dis.40, 1748–1755 (2005).
   PubMed Web of Science ®Google Scholar
• Arguedas A, Emparanza P, Schwartz RH, Soley C, Guevara S, de Caprariis PJ. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr. Infect. Dis. J.24(2), 153–161 (2005).
   PubMed Web of Science ®Google Scholar
• Soley CA, Arguedas A. Single-dose azithromycin for the treatment of children with acute otitis media. Expert. Rev. Anti Infect. Ther.3(5), 707–717 (2005).
   PubMedGoogle Scholar
• Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest128(4), 2230–2237 (2005).
   PubMed Web of Science ®Google Scholar
• Murray JJ, Emparanza P, Lesinskas E, Tawadrous M, Breen JD. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol. Head Neck Surg.133(2), 194–200 (2005).
   PubMed Web of Science ®Google Scholar
• Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1500 milligrams, given over a 3-or 5-day period in healthy subjects. Antimicrob. Agents Chemother.43, 163–165 (1999).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents18(Suppl. 1), S17–S23 (2001).
   PubMedGoogle Scholar
• Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647) – the first ketolide J. Antimicrob. Chemother.51, 497–511 (2003).
   PubMed Web of Science ®Google Scholar
• Contrepois A, Joly V, Abel L et al. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model. J. Antimicrob. Chemother.21, 621–631 (1988).
   PubMed Web of Science ®Google Scholar
• Chambers HF, Kennedy S. Effect of dosage, peak and trough concentrations in serum, protein binding and bactericidal rate of efficacy of teicoplanin in a rabbit model with endocarditis. Antimicrob. Agents Chemother.34, 510–514 (1990).
   PubMed Web of Science ®Google Scholar
• MacGowan A, White L, Reeves D et al. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J. Infect. Chemother.2, 197–208 (1996).
   PubMedGoogle Scholar
• Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J. Antimicrob. Chemother.51(4), 971–975 (2003).
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Candoni A et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin. Pharmacokin.43(6), 405–415 (2004).
   PubMed Web of Science ®Google Scholar
• Zimmerman AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcome in patients with Gram-positive bacteraemia. Pharmacotherapy15, 85–91 (1995).
   PubMed Web of Science ®Google Scholar
• Mulhern JG, Braden GL, O’Shea MH et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am. J. Kidney Dis.25, 611–615 (1995).
   PubMed Web of Science ®Google Scholar
• Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann. Pharmacother.28, 1335–1339 (1994).
   PubMed Web of Science ®Google Scholar
• Fernandez de Gatta MD, Calvo MV, Hernandez JM et al. Cost effectiveness analysis of serum vancomycin concentration monitoring in patients with haematologic malignancy. Clin. Pharmacol. Ther.60, 332–340 (1996).
   PubMed Web of Science ®Google Scholar
• Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy19(3), 257–266 (1999).
   PubMed Web of Science ®Google Scholar
• Ebert S. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and -resistant S. aureus. Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). American Society for Microbiology, Washington, DC, USA, 173, Abstract 439 (1987).
   Google Scholar
• Knudsen JD, Fuursted K, Espersen F, Frimodt-Moller N. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob. Agents Chemother.41, 1910–1915 (1997).
   PubMed Web of Science ®Google Scholar
• Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Møller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother.44(5), 1247–1254 (2000).
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Kagawa Y, Kojma M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol. Pharm. Bull.26(6), 876–879 (2003).
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis.42(Suppl. 1), S35–S39 (2006).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Cappelletty DM, Ruffing MJ et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for gram-positive infections. Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). American Society for Microbiology, Washington, DC, USA, 9, Abstract A-46 (1997).
   Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet.43, 925–942 (2004).
   PubMed Web of Science ®Google Scholar
• Drew RH, Lu I, Joyce M, Benjamin DK Jr, Fowler VG Jr. Lack of relationship between predicted area under the time-concentration curve/minimum inhibitory concentration and outcome in vancomycin-treated patients with Staphylococcus aureus bacteremia. Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA, 36, Abstract A-1493 (2004).
   Google Scholar
• Scaglione F. Can PK/PD be used in everyday clinical practice. Int. J. Antimicrob. Agents19(4), 349–353 (2002).
   PubMed Web of Science ®Google Scholar